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tionswere based in Asia (k4), North America (k3), Africa (k3) and Europe (k2).
The target population of these publications were the general public (k7), patients
(k4) or both (k1). A slight majority of the 12 primary evidence publications (k7)
and a larger majority of the 5 secondary evidence publications (k4) reported a SP
bias on the results of the BG. Various parameters such as male gender, higher
education and higher income levels were, in some instances, associated with
higherWTP amounts. Other factors analysed are the population surveyed (patients
vs. general population), and the location of the study. Association between these
factors and the occurrence of starting point bias is examined and will be reported.
CONCLUSIONS: There is evidence in the literature of a SP bias on the results of BGs,
without however a full consensus on the matter. Further research is warranted in
order to evaluate the conditions under which such bias appears.
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OBJECTIVES: Patient reported outcomes (PROs) have become an important compo-
nent of many clinical studies. The use of ePRO as a data collection method can
alleviate the potential burden experienced by patients and/or sites. The purpose of
this survey studywas to capture current PROdata collection trends and summarize
these findings side-by-sidewith results fromaprevious PROdata collection survey.
METHODS: Industry professionals were invited to complete a web-based survey
fielded in late 2011 and early 2012. This survey included questions on professional
demographics, experience using PROs (and ePROs) by study type and experience
with ePRO technologies. Responses were analyzed descriptively. RESULTS: To
date, 54 industry professionals completed the 2011-2012 survey. Fifty nine percent
of respondents were from pharmaceutical companies, biotech (26%), medical de-
vice (9%), and other (6%).While 49% of respondents in the 2010 survey had previous
PRO study experience, 60% of respondents in the current survey had previous PRO
experience. The proportion of respondents with prior ePRO experience, however,
was similar across the two surveys (51% in 2010 and 54% in 2011-2012). Hand-held
device (tablet, PDA) was the most common ePRO technology (71% in 2011, 64% in
2010), followed by interactive voice response (47% in 2011, 60% in 2010), and inter-
active web-response (29% in 2011, 51% in 2010). Among those with prior ePRO
exposure in 2011 and 2010, respectively, 59% and 86% strongly agreed/agreed they
would use ePRO in future studies. Among thosewho never used ePROs, 58% in 2011
and 50% in 2010 indicated they would likely use ePROs in future studies.
CONCLUSIONS: Results from this survey suggest that ePRO use continues to gain
moderate acceptance among industry professionals. These findings, however,
were based on a limited sample size. Future surveys should be administered to
allow future trends in ePRO use to be observed over time.
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OBJECTIVES: The Language Development Survey (LDS) assesses children’s word
combinations and vocabulary and provides an accurate picture of a child’s devel-
oping language when completed by a parent or guardian. The LDS contains a list of
310 basic words. The person completing the questionnaire is asked to circle those
words their child says spontaneously. Translations already existed in over ten
languages. Twelve further languages were translated, including eight Indic lan-
guages. A direct translation of some source words was not possible as some items
are unknown in the target country, e.g. pretzel, spaghetti, Sesame St. Therefore, it
was necessary to find a conceptually equivalent source word. METHODS: Two
approaches were adopted: An initial translatability assessment was carried out to
identify problematic words. Equivalent source words were suggested. Further
problematic words were identified during the translation and cognitive-debriefing
process. Alternatives were suggested either during the translation stages or by the
parent/guardian during the cognitive debriefing interview. Final wording was
agreed on through discussion with the lead in-country translator and instrument
developers. RESULTS: A number of cultural adaptations were made. For all Indian
languages, ‘cracker’ was translated as ‘papadom’ (a thin, crisp Indian cracker) and
‘pizza’ as translated as ‘dosa’ (a type of Indian pancake). This was decided before
the initial translation step. ‘Sesame St.’ was replaced with ‘Tom and Jerry’. In
French ‘saucisse’ was suggested as an alternative for ‘hot dog’ during cognitive
debriefing.CONCLUSIONS:When translating a patient-reported outcome (PRO) the
aim is to produce a translation that is conceptually equivalent to the source text. In
some cases, cultural adaptation is essential. Translation of the LDS is an excellent
example of this methodology and the translations are now available for use in
multi-national studies.
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OBJECTIVES: This session intends to identify patients’ preferences for receiving
reminders when participating in clinical trials. Results of a survey on patient ex-
periences will be reported. Recommendations for developing reminder strategies
will be provided with the intention of enhancing the patient’s experience and
compliance. METHODS: An internet survey was administered to patients (in De-
cember 2010) who participated in at least one clinical trial with patient diaries in
the past two years. The survey focused on patients’ perceived experiences and
preferences with patient diaries/ePRO, and how patient diary methods could be
improved. This session will focus on the questions relating to patient reminders–
specifically relating to preferences for how reminderswere sent/received, activities
for which reminders were found most useful, frequency of reminders, etc.
RESULTS: Reminder methods patients preferred most were email and text mes-
sages. Two areas patients preferred to be reminded about were any action required
of them as part of their clinical trial participation and when they were required to
record an electronic-diary entry. When patients were asked about how often they
wanted to receive reminders, the most frequent responses included whenever
there was new information related to their trial participation and once per day.
Patients also provided suggestions for reminders in future trials. CONCLUSIONS:
The results focus onwhat patients are telling industry what they do/do not want in
terms of reminders; these perspectives should be accounted for to enhance the
patient journey and compliance. If industry implements the reminder strategy
wrong (for instance, annoying patients by reminding them too frequently), that
may actually impact compliance negatively. Remind patients when necessary/not
too often. Remind patients in ways they will be able to best receive/notice them.
Appropriate use of reminders drives compliance and incorporating patient prefer-
ences will not only improve compliances rates, but will also enhance the patient’s
experience.
RESEARCH ON METHODS – Statistical Methods
PRM43
ROBUSTNESS OF CONFIDENCE INTERVALS FOR RARE EVENTS
Su Z1, Mendelsohn A1, Kim J2, Gemmen E3
1Outcome Sciences, a Quintiles Company, Cambridge, MA, USA, 2Quintiles Global Consulting,
London, Reading Berkshir, UK, 3Quintiles Global Consulting, Rockville, MD, USA
OBJECTIVES: Accurately estimating the upper bounds of confidence intervals for
rare events such as hospitalization or death is an important activity in safety stud-
ies and outcomes research. Confidence intervals, however, for rare events are sub-
ject to considerable variation based upon the overall sample size and total number
of observed events. This has led to a challenging convention that a minimum of 2
or 3 events are needed for computing meaningful confidence intervals. The objec-
tive of this study was to quantify the variation of the upper bound of confidence
intervals for a binomial proportion in the setting of rare events. METHODS: Clop-
per-Pearson confidence intervals were constructed for sample sizes ranging from
50 to 1000, and numbers of events from 0 to 5. The robustness of the confidence
interval was evaluated by calculating additional confidence intervals assuming: 1)
one more observed event than in the original sample and, 2) that the proportion of
events is equal to the upper bound of the confidence interval for the original
sample. RESULTS: With sample sizes of 50, 100, 200, 500 and 1000, the upper
bounds of the confidence intervals were 13.71%, 7.04%, 3.57%, 1.44% and 0.72%,
respectively, with 2 observed events in the original sample; 16.55%, 8.52%, 4.32%,
1.74% and 0.87%, respectively, (3 observed events); and, 26.40%, 13.94%, 7.16%,
2.91% and 1.47%, respectively, when the proportion of events was equal to the
upper bound of the confidence interval for the original sample with 2 events. Sim-
ilar trends were seen when using other numbers of observed events.
CONCLUSIONS: The upper bounds of confidence intervals for rare events vary
greatly with sample sizes and the numbers of events observed when the sample
size is small. A minimum of 500 subjects is optimal for constructing confidence
intervals for rare events, even if 2 events or less are observed.
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OBJECTIVES:Todevelop and test a three-way propensity scorematching algorithm
to provide pseudo-randomization of subjects into three groups to allow for com-
parable groups in a retrospective study. METHODS: Logistic regression using the
generalized multinomial logit linking function was used to calculate estimates of
the propensity score: the probability of having received three putatively inter-
changeable drugs from demographic (Race, Gender, Age) and comorbidities (Charl-
son Comorbidities Index) in a large, retrospective database. The most costly drug
was used as the reference group, and the probability of each treatment group
having received the reference drug was retained as the propensity score. In the
initial analysis 23,912, 4,789, and 4,318 individualswere available in the three treat-
ment regimens. Random subsets of 1/4 and 1/10 the original sample were con-
structed for the purpose assessing multi-group propensity score matching (PSM)
effectiveness in constructing comparable groups via pseudo-randomization with
varying starting sample sizes. PSM was conducted using calipers ranging from 8
digits to one digit of propensity score. Assessment of among-group differences
before and after PSM were conducted using Chi-square tests for categorical vari-
ables and GLM analysis, with difference scores and their confidence intervals for
continuous variables. RESULTS: For all sample sizes, prior to propensity score
matching, significant differences existed among the three treatment regimens for
all variables: gender, race, age and comorbidities. Following PSM there were 3381
matched triplets in the full sample. There were no significant differences among
groups for gender, age or comorbidities; there were significant but tiny differences
that remained for racial representation. In the smaller samples, 966 and 416
matched triplets were retained. There were no significant differences on any
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